<DOC>
	<DOCNO>NCT00359632</DOCNO>
	<brief_summary>To understand characterize effect linezolid optic nerve observe follow patient treat linezolid six week longer development sign symptoms visual disturbance eye disorder .</brief_summary>
	<brief_title>Study Evaluate Eye Function Patients Taking Linezolid Six Weeks Greater</brief_title>
	<detailed_description>Characterize Optic Side Effect</detailed_description>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>Male female subject 18 year age old . Subjects Treated Group : Subjects must receive linezolid 600 mg BID six week great currently drug ( receive linezolid within 7 day baseline evaluation ) . Subjects current sign symptom compatible linezolid toxicity ( i.e . optic peripheral neuropathy ) may enrol study linezolid time baseline evaluation ( receive linezolid within 7 day baseline evaluation ) . Linezolid may discontinue time primary physician 's discretion remain study . Women childbearing potential must use adequate contraception Subjects Control Group : Subjects diagnosis similar patient treat group similar important comorbidities epidemiologic factor possible . Subject Treated Group : Subjects know presence optic peripheral nerve damage due another illness , condition medication . Subjects preexist diagnosis time screen visit ophthalmologic condition would adversely affect study test protocol ( e.g . dense cataract , macular degeneration , retinitis pigmentosa ) . Subjects currently receive anticipate receive another medication , antibiotic , know potential produce ocular neurologic toxicity indistinguishable cause linezolid lactic acidosis . Subjects history significant exposure , opinion investigator prior discussion medical monitor , medication know produce optic peripheral neuropathy . Subjects active communicable disease ( i.e. , tuberculosis assess currently communicable ) subject active treatment tuberculosis mycobacterial disease include drug know potential produce ocular neurologic toxicity . Subjects severe liver disease abnormal liver function test . Subjects Control Group : Subjects must currently take linezolid receive 7 day time . Subjects know presence optic peripheral nerve damage due another illness , condition medication . Subjects preexist diagnosis screen visit ophthalmologic condition would adversely affect study test protocol ( e.g . dense cataract , macular degeneration , retinitis pigmentosa ) . Subjects currently receive another medication , antibiotic , know potential produce ocular neurologic toxicity indistinguishable cause linezolid lactic acidosis . Subjects history significant exposure , opinion investigator prior discussion medical monitor , medication know produce optic peripheral neuropathy . Subjects active communicable disease ( i.e. , tuberculosis assess currently communicable ) subject active treatment tuberculosis mycobacterial disease include drug know potential produce ocular neurologic toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Optic neuropathy follow long-term linezolid use</keyword>
</DOC>